Superselective Transarterial Chemoembolization for Hepatocellular Carcinoma: Recent Progression and Perspective
| Autor: | Kenichi Takayasu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
medicine.medical_specialty Carcinoma Hepatocellular Third party business.industry Liver Neoplasms Antineoplastic Agents General Medicine Prognosis medicine.disease Surgery Survival Rate Japan Oncology Doxorubicin Hepatocellular carcinoma Disease Progression medicine Humans Molecular Targeted Therapy Chemoembolization Therapeutic business Liver cancer Transcatheter arterial chemoembolization Neoplasm Staging |
| Zdroj: | Oncology. 81:105-110 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000333269 |
| Popis: | Transcatheter arterial chemoembolization (TACE) is widely performed in 32% of the patients with unresectable hepatocellular carcinoma (HCC) at initial diagnosis and in 58% of those with recurrent HCC in Japan. However, the patient population which undergoes TACE is heterogeneous, and thus the 3-year survival rate varies from 26 to 47%. The selection criteria for TACE is 2-3 tumors3 cm or 4 or more tumors in patients with liver damage A/B (corresponding well to Child-Pugh class A/B) and absence of vascular invasion and extrahepatic spread, as proposed by Japanese guidelines. The 3-year survival rate of TACE for patients with 2-3 tumors3 cm or 4 or more tumors was 55 and 46%, respectively, in Child-Pugh A and 30 and 22%, respectively, in class B. These outcomes could help to understand the various results of TACE in different backgrounds in the East and West. Recently, TACE with calibrated drug-eluting beads loaded with doxorubicin showed a similar tumor response and radioembolization with yttrium-90 microspheres demonstrated a similar median survival compared with conventional TACE. Based on these results, the combination of TACE and novel molecular targeted agents can be used to elucidate the synergic effect on survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|